安进公司宣布AMG 145可使高胆固醇血症患者低密度脂蛋白胆固醇降低40%~59%。AMG 145是一种人单克隆抗体,可抑制枯草溶菌素-9型前蛋白转化酶,即一种降低肝脏除去血液中低密度脂蛋白胆固醇能力的蛋白。AMG 145治疗12周后,制备超速离心法测定表明,低密度脂蛋白胆固醇较基线降低40%~59%,而安慰剂组仅为0.1%~0.5%(P<0.01)。用药组的其他脂质参数,包括高密度脂蛋白胆固醇、甘油三酯、载脂蛋白B和载脂蛋白A1均有改善。安全性分析中不良事件发生率,用药组高于安慰剂组,为57% Amgen has announced that AMG 145 will reduce LDL cholesterol in patients with hypercholesterolemia by 40% to 59%. AMG 145 is a human monoclonal antibody that inhibits subtilosin-9 type proprotein convertase, a protein that reduces the liver's ability to remove low-density lipoprotein cholesterol from the blood. After 12 weeks of treatment with AMG 145, the ultracentrifugation assay showed that LDL cholesterol was reduced by 40% -59% from baseline and only 0.1% -0.5% in the placebo group (P <0.01). Other lipid parameters in the medication group, including high-density lipoprotein cholesterol, triglycerides, apolipoprotein B, and apolipoprotein A1, were improved. In the safety analysis, the incidence of adverse events was higher in the medication group than in the placebo group, accounting for 57%